Pediatric Recurrent Brain Tumor Clinical Trial
Official title:
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with brain tumors that have returned or have been resistant to treatment.
| Status | Not yet recruiting |
| Enrollment | 7 |
| Est. completion date | December 31, 2030 |
| Est. primary completion date | January 31, 2029 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A to 25 Years |
| Eligibility | Eligibility Criteria for Tissue Sequencing (Step 1) Inclusion Criteria: - Any patient between the ages of 12 and 25 years of age (inclusive) who was diagnosed with a pediatric brain tumor of any histologic subtype, who has now developed recurrent or refractory disease. - All patients enrolled in this trial will receive standard of care treatment for recurrent and/or refractory pediatric brain tumors, including systemic agents, prior to receiving the investigational agent. - Availability of tissue for sequencing to determine presence of targetable neoantigen. This may be fresh tissue collected as part of routine care, another research project or archived tissue from a previous craniotomy with biopsy, subtotal resection, total gross resection, or re-resection. - Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable) or patient has a guardian who has the ability to understand and willingness to sign an IRB approved written informed consent document. Eligibility Criteria for Treatment Administration (Step 2) Step 2 Inclusion Criteria - Personalized neoantigen DNA vaccine manufactured for administration. - Karnofsky/Lansky performance status = 60% - Life expectancy > 24 weeks. - Prior therapy washout requirements (with exception of bevacizumab): - Myelosuppressive chemotherapy: Participants must have received their last dose of known myelosuppressive anticancer chemotherapy at least 3 weeks prior to first dose of vaccine (6 weeks prior if nitrosurea). - Biologic agent: Participant must have received their last dose of the biologic agent no less than 7 days prior to first dose of vaccine. - For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended to beyond the time during which adverse events are known to occur. The duration of this interval should be discussed with the study chair. - For biologic agents that have a prolonged half-life, the appropriate interval since last treatment should be discussed with the PI prior to first dose of vaccine. - Monoclonal antibody treatment: At least three half-lives must have elapsed prior to first dose of vaccine. Such participants should be discussed with the PI prior. - Bone Marrow Transplant: Participant must be: - = 6 months since allogeneic bone marrow transplant prior to first dose of vaccine. - = 3 months since autologous bone marrow/stem cell prior to first dose of vaccine. - Radiotherapy (in instances of lesions amenable to radiotherapy, such as bone metastases or metastases causing nerve impingement): At least 4 weeks must have elapsed prior to first dose of vaccine. - Investigational agents: At least 4 weeks must have elapsed prior to first dose of vaccine. - Normal bone marrow and organ function as defined below: - Absolute neutrophil count = 1.5 K/cumm - Platelets = 100 K/cumm - Hemoglobin level = 8 g/dL - Total bilirubin = 1.5 x institutional upper limit of normal (IULN) - AST(SGOT)/ALT(SGPT) = 3.0 x IULN - Creatinine = IULN OR creatinine clearance = 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal - Any adverse event patients may have experienced during prior therapy must have resolved to = CTCAE v5 grade 1. - Systemic corticosteroid therapy is permitted provided dosing is minimal based on age, defined as 0.1mg/kg/day with a max of 4mg daily (dexamethasone or equivalent) on the day of vaccine administration. Participants using topical, ocular, intra-articular, or intranasal/inhaled steroids may participate. Brief courses of corticosteroids for prophylaxis (eg, contrast dye allergy) or study treatment-related standard premedication are permitted. - Bevacizumab will be allowed if given for symptomatic control of vasogenic edema and to avoid high dose of corticosteroids. - Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Exclusion Criteria: - No candidate neoantigen identified during screening. - A history of other malignancy = 3 years previous with the exception of non-melanoma skin cancer, any in situ cancer that has been successfully resected and cured, treated superficial bladder cancer, or any early-stage solid tumor that was successfully resected without need for adjuvant radiation or chemotherapy. - Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty. - Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Ongoing or active infection requiring systemic therapy (e.g. active HBV or HCV infection that requires treatment) or causing fever (temperature > 38.1°C) or subjects with unexplained fever (temperature > 38.1°C) within 7 days prior to the first vaccine dose. - History of immunodeficiency disorder or autoimmune condition requiring active immunosuppressive therapy. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. - Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended. Recommend exclusion of specific ART agents based on predicted drug-drug interactions (i.e. for sensitive CYP3A4 substrates, concurrent strong CYP3A4 inhibitors (ritonavir and cobicistat) or inducers (efavirenz) should be contraindicated). - Administration of live vaccine within 30 days prior to first dose of vaccine. Participants may receive the COVID-19 vaccine as long as it is not a live vaccine. - Presence of clinically significant increased intracranial pressure (e.g. impending herniation) or hemorrhage, uncontrolled seizures, or requirement for immediate palliative treatment. - Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of first dose of vaccine. - Individuals in whom a measurement of the circumference of the thigh at the midpoint between the hip and knee is < 35 cm. - Individuals in whom a skinfold measurement of the cutaneous and subcutaneous tissue for eligible injection sites (left and right vastus laterals muscles) exceeds 50 mm. - Individuals in whom the ability to observe possible local reactions at the eligible injection sites is, in the opinion of the investigator, unacceptably obscured due to a physical condition (e.g. hypertrophic skin patches, keloids, or other conditions which could interfere with the administration procedure or subsequent assessment of local reactogenicity) or permanent body art. - Has a metal implant or implantable device within the area of the electroporation injection or has any non-removable electronic stimulation device, such as cardiac demand pacemaker, automatic implantable cardiac defibrillator, nerve stimulator, or deep brain stimulator. - Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical examination, EKG, and/or laboratory screening test. - Any chronic or active neurologic disorder, including seizures and epilepsy, excluding a single febrile seizure as a child. - Syncopal episode within 12 months of first dose of vaccine. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Washington University School of Medicine | Saint Louis | Missouri |
| Lead Sponsor | Collaborator |
|---|---|
| Washington University School of Medicine | Children's Discovery Institute |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Safety and tolerability of adjuvant personalized neoantigen DNA vaccine as measured by the number of grade 3 and 4 adverse events | Through 30 days after completion of treatment (estimated to be 13 months) | ||
| Primary | Feasibility of adjuvant personalized neoantigen DNA vaccine as measured the number of participants that had a neoantigen-specific DNA vaccine generated | From time of resection to time of initiation (approximately 12-14 weeks) | ||
| Secondary | Median Progression Free Survival (PFS) | PFS is defined as the duration of time from date of first dose of vaccine to date of progression or evidence of last progression free time.
Progressive Disease (PD): At least a 25% increase in the sum of products of perpendicular diameters of at least 1 target lesion, taking as reference the smallest sum of products of perpendicular diameters on study (this includes the baseline sum if that is the smallest on study). The absolute increase in any dimension must be at least 5mm when calculating the products of perpendicular diameters. Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy* not caused by comorbid events. |
2 years | |
| Secondary | Median Overall Survival | -OS is defined as date of first dose of vaccine to date of death or date of last known alive. | 2 years |